Long Term Clinical Evidence and Worldwide Increase in Patients Treated with the CyberKnife System SUNNYVALE, Calif., Aug. 30, 2011 /PRNewswire via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today a significant increase in use of the CyberKnife®
Next-Generation Accuray Precision® Treatment Planning System With the CyberKnife VOLO™ Optimizer Also Reduces Treatment Planning Times Up to 90 Percent, Enabling Clinicians to Treat More Patients Each Day SUNNYVALE, Calif. , Dec. 6, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY)
SUNNYVALE, Calif. , July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new clinical studies presented at the 15 th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKnife® platform
SUNNYVALE, Calif. , Jan. 8, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the CyberKnife ® System provided excellent disease control with low rates
- Prospective, randomized, international multicenter study - PACE - Prostate Advances in Comparative Evidence - results presented at ESTRO 2021 - Bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment
7,000 Patient Single Institution Analysis Shows Safety, Versatility and Increasing Use of the Advanced Radiotherapy Platform Over a 20-Year Timeframe SUNNYVALE, Calif. , Nov. 10, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that more than two
SUNNYVALE, Calif. , Oct. 25, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast
- Trigeminal neuralgia, a persistent neurological disorder, is described by some patients as the most excruciating pain human beings can experience(1) - The approval expands global patient access to the CyberKnife System, an effective, non-invasive treatment alternative to surgery SUNNYVALE, Calif.
- Results Demonstrate Exceptional Treatment Plan Quality Achievable with Accuray Treatment Planning Software (TPS) - Renowned Clinical Trials Group TROG Cancer Research and ProKnow Partnered to Host Study SUNNYVALE, Calif. , May 22, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY)
Data Highlight Expanding Use of (Ultra) Hypofractionated Treatments, Benefits in Patient Care Made Possible by the Precision and Accuracy of Accuray Technologies SUNNYVALE, Calif. , May 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
